Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 626

1.

Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas.

Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB.

Nat Commun. 2015 Jan 28;6:4852. doi: 10.1038/ncomms5852. No abstract available.

PMID:
25629879
[PubMed - in process]
2.

Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors.

Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Mills Shaw K, Mendelsohn J, Mills GB, Karina Eterovic A.

Clin Chem. 2015 Jan 27. pii: clinchem.2014.231100. [Epub ahead of print]

PMID:
25626406
[PubMed - as supplied by publisher]
3.

Functional consequence of the MET-T1010I polymorphism in breast cancer.

Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM.

Oncotarget. 2014 Dec 31. [Epub ahead of print]

PMID:
25605252
[PubMed - as supplied by publisher]
Free Article
4.

Shrewd AKT regulation to survive.

Dawood M, Mills GB, Ding Z.

Oncoscience. 2014 Mar 17;1(2):113-4. eCollection 2014. No abstract available.

PMID:
25594004
[PubMed]
Free PMC Article
5.

RET fusion as a novel driver of medullary thyroid carcinoma.

Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE, Lu X, Lu H, Meric-Bernstam F, Mills GB, Palmer G, Perrier ND, Scott KL, Shaw KR, Waguespack SG, Williams MD, Yelensky R, Cote GJ.

J Clin Endocrinol Metab. 2014 Dec 29:jc20144153. [Epub ahead of print]

PMID:
25546157
[PubMed - as supplied by publisher]
6.

α-Tubulin Acetylation Elevated in Metastatic and Basal-like Breast Cancer Cells Promotes Microtentacle Formation, Adhesion, and Invasive Migration.

Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS.

Cancer Res. 2015 Jan 1;75(1):203-15. doi: 10.1158/0008-5472.CAN-13-3563. Epub 2014 Dec 12.

PMID:
25503560
[PubMed - in process]
7.

Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB.

Cancer Cell. 2014 Dec 8;26(6):863-79. doi: 10.1016/j.ccell.2014.10.010.

PMID:
25490449
[PubMed - in process]
8.

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Berg A, Hoivik EA, Mjøs S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Oyan AM, Kalland KH, Cherniack AD, Beroukhim R, Stefansson I, Mills GB, Krakstad C, Salvesen HB.

Oncotarget. 2014 Nov 4. [Epub ahead of print]

PMID:
25415225
[PubMed - as supplied by publisher]
Free Article
9.

In silico prediction of physical protein interactions and characterization of interactome orphans.

Kotlyar M, Pastrello C, Pivetta F, Lo Sardo A, Cumbaa C, Li H, Naranian T, Niu Y, Ding Z, Vafaee F, Broackes-Carter F, Petschnigg J, Mills GB, Jurisicova A, Stagljar I, Maestro R, Jurisica I.

Nat Methods. 2015 Jan;12(1):79-84. doi: 10.1038/nmeth.3178. Epub 2014 Nov 17.

PMID:
25402006
[PubMed - in process]
10.

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL.

J Clin Invest. 2014 Dec 1;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17.

PMID:
25401474
[PubMed - in process]
11.

Development of a robust classifier for quality control of reverse-phase protein arrays.

Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, Davies MA, Akbani R, Weinstein JN, Mills GB, Coombes KR.

Bioinformatics. 2014 Nov 6. pii: btu736. [Epub ahead of print]

PMID:
25380958
[PubMed - as supplied by publisher]
12.

Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks.

Chiu H, Llobet-Navas D, Yang X, Chung W, Ambesi-Impiombato A, Iyer A, Kim HR, Seviour EG, Luo Z, Sehgal V, Moss T, Lu Y, Ram P, Silva J, Mills GB, Califano A, Sumazin P.

Genome Res. 2014 Nov 5. pii: gr.178194.114. [Epub ahead of print]

PMID:
25378249
[PubMed - as supplied by publisher]
13.

Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation.

Kim TH, Yoo JY, Kim HI, Gilbert J, Ku BJ, Li J, Mills GB, Broaddus RR, Lydon JP, Lim JM, Yoon HG, Jeong JW.

Cancer Res. 2014 Dec 15;74(24):7371-82. doi: 10.1158/0008-5472.CAN-14-0794. Epub 2014 Nov 6.

PMID:
25377472
[PubMed - in process]
14.

A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data.

Liu W, Ju Z, Lu Y, Mills GB, Akbani R.

Cancer Inform. 2014 Oct 16;13:109-17. doi: 10.4137/CIN.S13329. eCollection 2014.

PMID:
25374453
[PubMed]
Free PMC Article
15.

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.

Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM.

J Cancer. 2014 Oct 15;5(9):745-53. doi: 10.7150/jca.9696. eCollection 2014.

PMID:
25368674
[PubMed]
Free PMC Article
16.

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB, Hennessy BT.

Mol Cancer. 2014 Oct 24;13:241. doi: 10.1186/1476-4598-13-241.

PMID:
25344116
[PubMed - in process]
Free PMC Article
17.

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA.

Cancer Res. 2014 Dec 1;74(23):7037-47. doi: 10.1158/0008-5472.CAN-14-1392. Epub 2014 Oct 8.

PMID:
25297634
[PubMed - in process]
18.

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.

Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW.

Oncogene. 2014 Oct 6. doi: 10.1038/onc.2014.328. [Epub ahead of print]

PMID:
25284585
[PubMed - as supplied by publisher]
19.

Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

Cheung LW, Yu S, Zhang D, Li J, Ng PK, Panupinthu N, Mitra S, Ju Z, Yu Q, Liang H, Hawke DH, Lu Y, Broaddus RR, Mills GB.

Cancer Cell. 2014 Oct 13;26(4):479-94. doi: 10.1016/j.ccell.2014.08.017. Epub 2014 Oct 2.

PMID:
25284480
[PubMed - indexed for MEDLINE]
20.

Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.

Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, Hoivik EA, Mills GB, Krakstad C, Salvesen HB.

Eur J Cancer. 2014 Nov;50(17):3003-10. doi: 10.1016/j.ejca.2014.09.003. Epub 2014 Sep 30.

PMID:
25281525
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk